At a glance
ClinicalIndex Comparison Record- ✓ARID1A-mutated endometrial cancer with loss of function mutations confirmed by CLIA-certified NGS
- ✓Measurable disease per RECIST 1.1 with specific size criteria
- ✓At least one prior chemotherapeutic regimen for endometrial carcinoma
- ✓Prior PD-1/PD-L1 immunotherapy (up to 50% may be exempted)
- ✕Chemotherapy, immunotherapy, investigational therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C)
- ✕Adverse events from prior anti-cancer therapy not recovered to Grade 1 or less
- ✕Meningeal carcinomatosis
- ✕Severe hypersensitivity to avelumab or M1774 or monoclonal antibodies, or anaphylaxis history
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Avelumab in Combination With ATR Inhibitor M1774 in Patients With ARID1A-mutated Recurrent Endometrial Cancer Who Have Received Prior Immunotherapy
In Brief
A Phase 2 clinical trial evaluating Avelumab and M1774 for Endometrial Cancer and 2 related conditions. Currently recruiting, targeting 25 participants across 2 sites.
Detailed Summary
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)
Study Details
Timeline
Interventions
Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.
Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.